Search for a trial

Assessing and predicting functional and quality of life-related outcomes of islet and pancreatic transplantation in patients with type 1 diabetes mellitus

There are two objectives for this study: first, to find specific serum beta cell damage markers that can serve as a clinical predictive tool for beta cell allograft loss. Second, to compare quality of life and diabetes-related outcomes in patients…

Mechanisms of Albuminuria in Diabetes: Reversal of Injury to the Glycocalyx by the Ace-inhibitor Lisinopril

The primary objective of this study is to determine whether ACE inhibition results in an improvement of microvascular glycocalyx-thickness in patients with type 1 diabetes. The secondary objectives are to investigate whether this (hypothesized)…

Open-label Phase-4 study to examine the change of vision-related quality of life in subjects with diabetic macular edema (DME) during treatment with intravitreal injections of 2 mg aflibercept according to EU label for the first year of treatment.

Primary objectiveTo evaluate the change in quality of life (NEI VFQ 25) in subjects with DME during the first year of treatment with aflibercept according to the EU label for DMESecondary objectives• To assess further the safety and tolerability of…

An Open Label, Phase IV, Mechanistic, Study to Evaluate the Natriuretic Effect of 2-Week Dapagliflozin treatment in Type 2 Diabetes Mellitus Patients with Impaired Renal Function

The central hypothesis of this study is that dapagliflozin drives a natriuretic effect independently of renal function level. The study will therefore evaluate average 24-hr sodium excretion during dapagliflozin treatment in patients with T2DM with…

DiEtary Sodium Intake effects on ertugliflozin-induced changes in GFR, reNal oxygenation and systemic hemodynamics: the DESIGN study, a randomized, placebo-controlled, cross-over study with ertugliflozin in people with type 2 diabetes

This study has been transitioned to CTIS with ID 2023-510257-42-01 check the CTIS register for the current data. Sodium-glucose cotransporter 2 (SGLT2) inhibitors lead to a lowering of blood pressure and confer cardiovascular and renal protection in…